Karalus Jolanta, Chlebna-Sokół Danuta
Department of Pediatrics Propedeutics and Bone Metabolic Diseases, Medical University of Lodz, Poland.
Pediatr Endocrinol Diabetes Metab. 2011;17(1):35-40.
Vitamin D supplementation in prevention and treatment of osteoporosis is a widely accepted standard, but the latest studies show the necessity of increasing the intake of this vitamin to keep its concentration on higher levels - above 30 ng/ml. The best index describing the body vitamin D supply is hepatic metabolite of vitamin D (25OHD) concentration in the serum. There are few data on efficacy of this vitamin intake in children with low bone mass. AIM OF THE STUDY was to find out if vitamin D supplementation causes a significant increase in the hepatic metabolite concentrations and how it affects the clinical course of the disease and the results of densitometric tests in children with primary low bone mass.
Seventy six children aged 6 to 18.5 years (35 girls and 41 boys) with primary osteoporosis or low bone mass diagnosed based on clinical and densitometric signs were included in the study. In all children, the concentrations of 25OD and PTH were measured and densitometric evaluations were taken twice, before and after 1 year of vitamin D intake. According to literature data, 30 ng/ml was adopted as the lower limit of normal 25OHD levels in children with osteoporosis and low bone mass.
Vitamin D supplementation for 12 months of osteoporosis and low bone mass therapy in children caused a statistically significant increase in concentrations of the hepatic metabolite of vitamin D and a significant reduction in serum PTH levels. The changes in 25OHD levels depended on the vitamin D dose used (658 IU/day), and only this amount allowed to achieve an improvement in the densitometric parameters, in particular the increase in bone mineral density (BMD) in the lumbar spine.
补充维生素D以预防和治疗骨质疏松症是一项被广泛接受的标准,但最新研究表明,有必要增加这种维生素的摄入量,以使血清浓度维持在较高水平——高于30 ng/ml。描述体内维生素D供应情况的最佳指标是血清中维生素D的肝脏代谢产物(25OHD)浓度。关于维生素D摄入量对低骨量儿童的疗效数据较少。本研究的目的是确定补充维生素D是否会使肝脏代谢产物浓度显著升高,以及它如何影响原发性低骨量儿童的疾病临床进程和骨密度检测结果。
本研究纳入了76名年龄在6至18.5岁之间(35名女孩和41名男孩)的儿童,他们根据临床和骨密度体征被诊断为原发性骨质疏松症或低骨量。所有儿童均测量了25OD和甲状旁腺激素(PTH)的浓度,并在摄入维生素D 1年前和1年后进行了两次骨密度评估。根据文献数据,骨质疏松症和低骨量儿童的正常25OHD水平下限设定为30 ng/ml。
对儿童进行12个月的骨质疏松症和低骨量治疗补充维生素D后,维生素D的肝脏代谢产物浓度有统计学显著升高,血清PTH水平显著降低。25OHD水平的变化取决于所使用的维生素D剂量(658 IU/天),只有这个剂量能够改善骨密度参数,特别是腰椎骨矿物质密度(BMD)的增加。